Marina Biotech said this week that it has priced an underwritten public offering of 6.375 million units of stock and warrants at $0.80 each, for total gross proceeds of $5.1 million.
Each unit, Marina said, consists of one share of common stock and 0.1746 of a warrant to buy one share of common stock. The warrants are exercisable immediately and have a seven-year term.
The offering is expected to close mid-February, the company added.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
